Cynata Therapeutics Limited · ASX:CYP
Cynata Therapeutics — Shareholder Meeting (November 2023)
25 slides from Cynata Therapeutics's shareholder meeting presentation, Nov 13, 2023
Slide 1: A Next Generation Stem Cell Therapeutics Company
A Next Generation Stem Cell Therapeutics Company Managing Director’s Presentation Dr Kilian Kelly Annual General Meeting 13 November 2023
Slide 2: Important information
Important information Summary information ‘propose’, ‘will’, ‘believe’, ‘forecast’, ‘estimate’, ‘target’, ‘outlook’, ‘guidance’, ‘potential’ and other similar This Presentation contains summary information about Cynata Therapeutics Limited and its subsidiaries expressions. The forward looking statem
Slide 3: Company highlights
Company highlights Cynata is a clinical stage biotech developing its proprietary Cymerus platform technology for the scalable manufacture of mesenchymal stem cell (MSC) therapeutic products to treat serious disorders Unique Strong safety Large Multiple Well funded Manufacturing and efficacy addressa
Slide 4: Cynata has an advanced and diverse clinical pipeline
Cynata has an advanced and diverse clinical pipeline Target area Trial phase Market opportunity Acute Graft vs Host Disease (aGvHD) Cynata Sponsored CYP-001 Phase 2 underway US$600m1 Diabetic Foot Ulcers (DFU) Phase 1 underway US$9.6bn2 CYP-006TK Osteoarthritis (OA) CYP-004 Phase 3 underway US$11.6b
Slide 5: Why Mesenchymal Stem Cells (MSCs)?
Why Mesenchymal Stem Cells (MSCs)? MSCs play a central co-ordinating role in many of the body’s mechanisms of defence, repair and regeneration: 1 the “sensor and switcher of the immune system” MSCs can be used therapeutically without matching the donor and the recipient MSCs promote an immunomodulat
Slide 6: Manufacturing
Gulplalla therapeutics Manufacturing
Slide 7: Cynata's process utilizes induced pluripotent stem cells (iPSCs)
Cynata’s process utilizes induced pluripotent stem cells (iPSCs) • iPSCs are mature cells from adult donors that are reprogrammed to be capable of: − effectively limitless proliferation in cell culture − differentiation into any adult cell type (including MSCs) Thus an ideal starting material for ce
Slide 8: Cymerus iPSC-based manufacturing process
Cymerus™ iPSC-based manufacturing process Cells donated Conventional process MSCs Conventional Cells from MSC isolation MSC culture Final product multiple donors process expansion Major challenges include inter-donor variability and functional changes Large number of Substantial variability Limited
Slide 9: Strategic partnership with Fujifilm provides commercial benefits
Strategic partnership with Fujifilm provides commercial benefits Cynata executed a Strategic Partnership Agreement with Fujifilm, with Fujifilm involved in the path to market1 Strategic benefits for Cynata Fujifilm is one of the largest conglomerates in the world with a significant network and ass
Slide 10: Preclinical Data
Gulplalla therapeutics Preclinical Data
Slide 11: Cymerus MSCs: Completed Preclinical Studies
Cymerus MSCs: Completed Preclinical Studies Indication Partner Key highlights References Cymerus MSCs attenuated disease severity and prolonged survival in a humanised mouse model of GvHD Ozay et al, Stem Cell Res Graft versus Host Disease 2019;35:101401 Novel wound dressing seeded with Cymerus MSCs
Slide 12: MSCs from different sources have different properties
MSCs from different sources have different properties Key Findings include: • Source is the primary driver of MSC heterogeneity (variability) • Cymerus MSCs differ from tissue-derived MSCs by upregulation of biological processes linked to telomere maintenance and RNA catabolism, and downregulation o
Slide 13: MSC source also influences performance in preclinical models
MSC source also influences performance in preclinical models Pre-clinical rat model of myocardial ischemia- Preclinical mouse model of diabetic wounds, using reperfusion (heart attack)1 novel MSC-seeded dressing 100 Positive effects were observed with both Cymerus MSCs and 90 Percentage re-epithelia
Slide 14: Clinical Trials
Gulplalla therapeutics Clinical Trials
Slide 15: aGvHD | Phase 1 clinical trial (completed)
aGvHD | Phase 1 clinical trial (completed) The first completed clinical trial of an iPSC-derived product Published in Nature Medicine3 Complete 53% Overall 87% 2yr 60% response response survival No treatment-related serious adverse events or safety concerns identified - Subjects received 1x106 cells
Slide 16: aGvHD | Phase 2 clinical trial
aGvHD | Phase 2 clinical trial Product • CYP-001 (Cymerus™ iPSC-derived MSCs for intravenous infusion) • Acute graft versus host disease (aGvHD) may occur after bone marrow transplantation and similar Indication procedures, due to donor immune cells (from the “graft”) attacking the transplant recipi
Slide 17: DFU | Phase 1 clinical trial
DFU | Phase 1 clinical trial Product • CYP-006TK (Novel silicone dressing seeded with Cymerus™ iPSC-derived MSCs) Indication • Diabetic Foot Ulcers (DFU) are wounds on the feet of patients with diabetes • Randomised controlled trial in ~30 patients with DFU Trial Details • Clinical sites in Australi
Slide 18: DFU | CYP-006TK initial treatment data
DFU | CYP-006TK initial treatment data Great ulcer surface area healed in CYP-006TK group compared to standard of care (SoC) Mean % ulcer surface area healed over time (%)1; n=6 (3 in each group) 100 Mean CYP-006TK Mean SoC 80 60 40 20 0 0 7 14 21 28 Days 1. Mean defined as average ulcer surface are
Slide 19: OA | Phase 3 clinical trial
OA | Phase 3 clinical trial1 Product • CYP-004 (Cymerus™ iPSC-derived MSCs for intra-articular injection) • Osteoarthritis (OA) occurs when the cartilage in a joint wears away. It causes pain, inflammation, Indication swelling and difficulty with movement. • Trial conducted by University of Sydney,
Slide 20: Renal transplantation | Phase 1 clinical trial
Renal transplantation | Phase 1 clinical trial Product • CYP-001 (Cymerus™ iPSC-derived MSCs for intravenous infusion) • Current standard of care after kidney transplantation involves long-term requirement for anti-rejection Indication drugs, which often cause serious toxicities • Trial to be conduc
Slide 21: Corporate Information
Gulplalla therapeutics Corporate Information
Slide 22: Board & Senior Management
Board & Senior Management Highly skilled and experienced senior leadership team with decades of experience Dr Kilian Kelly Dr Geoff Brooke Chief Executive Officer & Independent Non-Executive Chair Managing Director • 30+ years' experience in the healthcare • 20+ years' experience in biopharma R&D in
Slide 23: Corporate overview
Corporate overview Cynata has been listed on the Australian Securities Exchange (ASX) since 2013 (Ticker: CYP) Shareholder distribution Substantial shareholders (>5%) 52% Bioscience Managers 13.1% Fidelity Remaining Top 20 Bioscience Managers is an international healthcare investment firm 25% Other
Slide 24: Investment summary
Investment summary • Leading technology in burgeoning stem cell sector Next generation stem cell company • Diverse and highly credentialed leadership team with proven clinical and commercial experience across a range of health sciences at leading institutions • Patented Cymerus manufacturing technol
Slide 25: Contact Us
Contact Us Cynata Therapeutics Limited Contact details: Level 3 100 Cubitt Street info@cynata.com Cremorne Victoria 3121 www.cynata.com Australia
Cynata Therapeutics — Shareholder Meeting (November 2023) on 6ix